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Abstract. Caveolin is a protein associated with the 
characteristic coats that decorate the cytoplasmic face 
of plasma membrane caveolae. Recently it was found 
that exposure of human fibroblasts to cholesterol oxi- 
dase (CO) rapidly induces caveolin to redistribute to 
the ER and then to the Golgi complex, and that subse- 
quent removal of CO allows caveolin to return to the 
plasma membrane (Smart, E. J., Y. -S. Ying, P. A. Con- 
rad, R. G. W. Anderson. J. Cell Biol. 1994. 127:1185- 
1197). We now present evidence that caveolin normally 
undergoes microtubule-dependent cycling between the 
plasma membrane and the Golgi. In cells that were 
treated briefly with nocodazole and then with a mixture 
of nocodazole plus CO, caveolin relocated from the 
plasma membrane to the ER and then to the ER/Golgi 
intermediate compartment (ERGIC), but subsequent 
movement to the Golgi was not observed. Even in the 
absence of CO, nocodazole caused caveolin to accumu- 
late in the ERGIC. Nocodazole did not retard the 
movement of caveolin from the Golgi to the plasma 
membrane after removal of CO. Incubation of cells at 
15  ° followed by elevation of the temperature to 37  ° 
caused caveolin to accumulate first in the ERGIC and 
then in the Golgi, before finally reestablishing its nor- 
mal steady state distribution predominantly in plasma 
membrane caveolae. In cells released from a 15  ° block, 
movement of caveolin from the Golgi to the plasma 
membrane was not inhibited by nocodazole. Taken to- 
gether, these results imply that caveolin cycles constitu- 
tively between the plasma membrane and the Golgi by 
a multi-step process, one of which, ERGIC-to-Golgi 
transport, requires microtubules. This novel, bidirec- 
tional pathway may indicate roles for microtubules in 
the maintenance of caveolae, and for caveolin in shut- 
tling fatty acids and cholesterol between the plasma 
membrane and the ER/Golgi system. 
IN  fibroblasts  and many other cell types, microtubules 
1  |  (MTs)  radiate outward from a perinuclear MT-orga- 
nizing  center  (MTOC),  with  their  minus  ends  an- 
chored at the MTOC and their plus ends facing the cell pe- 
riphery. MTs oriented in this manner serve as intracellular 
"highways" along which  tubulovesicular transport inter- 
mediates of the secretory and endocytic pathways travel 
between the cell center, where the Golgi complex and ly- 
sosomes  are located, and the plasma membrane, where 
materials are exchanged between the extracellular envi- 
ronment and the cytoplasm. As a consequence of their ra- 
dial organization in the cell and their involvement in en- 
domembrane transport, MTs are responsible for maintaining 
the normal intracellular locations and organization of nu- 
merous quasi-stable  membrane systems, including the ER 
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(30), the Golgi (8, 18, 31, 33), and late endosomes and ly- 
sosomes (13, 22, 29). 
By comparison,  little has been known about the role of 
MTs in maintaining the structure and localization  of cav- 
eolae.  These  flask-shaped  invaginations of  the  plasma 
membrane, typically 50-100  nm in diameter, have been 
observed in most cell types and evidently serve  multiple 
functions. Classically, caveolae have been known for their 
involvement in transcytosis in endothelial cells (14). More 
recently, they were identified as the sites for folic acid up- 
take by a process called potocytosis (1, 2). During potocy- 
tosis the caveola undergoes an internalization cycle that 
involves formation of a closed compartment called a plas- 
malemmal vesicle, release of folic acid into the cytoplasm 
and reformation of an open caveola.  There is  evidence 
that  caveolae  have  a  high  concentration of glycolipids, 
sphingomyelin, and cholesterol (4, 28), as well as a protein 
called caveolin  (19). They are also the collecting sites for 
multiple glycosylphosphatidylinositol (GPI)-anchored  mem- 
brane proteins (5, 35). The recent finding that isolated cav- 
eolae contain a variety of signal transducing molecules (5, 
12, 21, 26) suggests that, in addition, they play a role in cell 
signaling (1). 
A  totally unexpected aspect  of caveolar behavior was 
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been incubated with the membrane impermeable enzyme, 
cholesterol oxidase (CO), which caused oxidation of cho- 
lesterol in caveolae (28).  Localization of caveolin with a 
monoclonal antibody revealed immunoreactive protein to 
be mainly in caveolae in unperturbed cells. In cells treated 
with CO, however, caveolin redistributed to the Golgi ap- 
paratus.  Caveolin first appeared in the rough ER during 
CO-induced  transport,  and  then  migrated  to  the  Golgi. 
Subsequent removal of CO quickly led to the return of ca- 
veolin to caveolae. In contrast to the striking effects of CO 
on caveolin, CO did not alter the morphology or number 
of caveolae in any obvious manner (28). It appears, there- 
fore, that CO does not induce intact caveolae to move to 
the Golgi. 
The effects of CO on caveolin traffic raised several im- 
portant questions, two of which are addressed in the cur- 
rent report. First, are MTs required for the inward move- 
ment  of  caveolin  in  CO-treated  cells  or  the  outward 
movement of caveolin that follows CO removal? Second, 
did CO reveal a normal cyclic transport pathway for cave- 
olin  between  the  cell surface  and  the  Golgi,  or alterna- 
tively, did it artifactually induce a redistribution of caveo- 
lin to an ectopic location? These questions were addressed 
by immunofluorescence and immunoelectron microscopy, 
and biochemical analysis of normal human fibroblasts that 
had  been  perturbed  chemically  with  CO  and  the  MT- 
depolymerizing drug, nocodazole, and physically by expo- 
sure to 15  °. The net results indicate that caveolin does, in- 
deed, cycle constitutively between caveolae and the Golgi, 
and that the inward,  but not the outward movement re- 
quires  MTs.  This  study  provides  the  first  evidence  that 
MTs are needed to maintain the normal distribution of a 
resident caveolar protein, and also reveals a novel, bidirec- 
tional pathway for the exchange of materials between the 
plasma membrane and the Golgi complex. Caveolin may 
follow this  pathway to shuttle  lipids  and  cholesterol be- 
tween the cell surface and the ER/Golgi membrane system. 
Materials and Methods 
Materials 
Materials were purchased from the following sources: DME, glutamine, 
trypsin-EDTA, and penicillin/streptomycin: GIBCO BRL (Gaithersburg, 
MD); FBS: Hazleton Research Products, Inc. (Lenexa, KS); cholesterol 
oxidase (from Nocardia erythropolis):  Boehringer Mannheim (Indianapo- 
lis, IN); nocodazole, trypsin, soybean trypsin inhibitor, and DABCO (1,4- 
diazabicyclo-(2,2,2) octane): Sigma Chem. Co. (St. Louis, MO); Percoll: 
Pharmacia LKB Biotechnology (Piseataway, NJ); Fluoromount G: South- 
ern  Biotechnology  Associates, Inc.  (Birmingham, AL);  "SuperSignal" 
chemiluminescent reagent: Pierce (Rockford, IL); HRP-labeled goat anti- 
mouse IgG,  and TRITC-goat  anti-mouse IgG:  Cappel  (West Chester, 
PA), FITC-goat anti-mouse IgM: Zymed Laboratories  (San Francisco, 
CA); FITC-goat anti-rabbit IgG and CY5-donkey anti-rabbit IgG: Jack- 
son ImmunoResearch Labs (West Grove, PA); goat anti-mouse IgG con- 
jugated to 10 nm gold: Energy Beam Sciences (Agawam, MA). 
The following primary antibodies were generously provided as gifts: a 
monoclonal mouse IgG against caveolin (mAb 2234) from Dr. John Glen- 
ney of Glentech, Inc. (Lexington, KY) (19); a polyclonal rabbit antiserum 
against human galactosyltransferase from Dr. Eric Berger of the Univer- 
sity of Zurich (Zurich, Switzerland) (3); polyclonal rabbit antisera against 
the EAGE peptide of I3-COP from Drs. Thomas Kreis of the University 
of Geneva (Geneva, Switzerland) (17) and Jennifer Lippincott-Schwartz 
of the NIH (Bethesda, MD)  (10); a  monoclonal mouse IgG specific for 
ERGIC:53 from Dr. Hans-Peter Hauri of the University of Basel (Basel, 
Switzerland)  (23); a  polyclonal rabbit antiserum against the human low 
density lipoprotein  (LDL)  receptor  from Dr.  Joseph Goldstein of UT 
Southwestern; a polyclonal antibody against cathepsin D  from Dr. Will- 
iam Brown of Cornell University (15).  In addition, a monoclonal mouse 
IgM against tubulin (34) was obtained from hybridoma cells grown in the 
Bloom laboratory. 
Cell Culture 
Human fibroblasts were derived from a skin biopsy obtained from a nor- 
mal patient, and were grown in monolayer culture in DME supplemented 
with penicillin/streptomycin and 10% FBS. For the temperature block ex- 
periments, cells were incubated for 2 h at 15  ° in DME +20 mM Hepes at 
pH 7.4, and then were returned to 37  °. Nocodazole was diluted from a 10- 
raM stock in DMSO, and was used at a final concentration of 40 ixM. CO 
was used at a final concentration of 0.5 U/ml (1 U  of activity converts 1 
p.mol of cholesterol to cholestenone in 1 min). 
Immunofluorescence and Immunoelectron Microscopy 
All procedures for indirect immunofluorescence were performed at room 
temperature, 0.1  M  phosphate buffer at pH 7.2,  was used for all  rinse 
steps, and all primary and secondary antibodies were diluted into phos- 
phate buffer containing 10 mg/ml BSA. Cells grown on glass coverslips 
were fixed for 30 min in phosphate buffer containing 4% p-formaldehyde, 
and permeabilized with 0.05 % Triton X-100 in phosphate buffer for 2 min. 
Incubations with primary and secondary antibodies were for 30 min each. 
For double and triple immunofluorescence experiments, the primary and 
secondary antibodies were mixed together for the first and second incuba- 
tion steps, respectively. For double immunofluorescence, the primary an- 
tibodies were mouse monoclonal IgG against caveolin or ERGIC-53, and 
rabbit polyclonal anti-13-COP, anti-cathepsin D or anti-LDL receptor; and 
the secondary antibodies were TRITC-goat anti-mouse IgG and FlTC-goat 
anti-rabbit IgG. For triple immunofluorescence, the primary antibodies 
were mouse anti-caveolin (monoclonal IgG), mouse anti-tubulin (mono- 
clonal IgM) and rabbit polyclonal anti-13-COP, and the secondary anti- 
bodies were TRITC-goat anti-mouse IgG, FITC-goat anti-mouse IgM 
and  CY5-donkey  anti-rabbit  IgG.  Coverslips  were  mounted  on  glass 
slides using Fluoromount G  +2.5% DABCO. 
Procedures for immuno-EM localization of caveolin and 13-COP were 
exactly as  described previously (28).  All  immunofluorescence and  im- 
muno-EM experiments were performed as detailed time courses in which 
several antigens were localized at each time point. For example, cells were 
fixed after a 2-h incubation at 15  °, and after subsequent transfer to 37  °, ev- 
ery 5 min for 2 h. At each time point in this case, cells were examined by 
double or triple immunofluorescence  for caveolin, 13-COP, ERGIC-53, ga- 
lactosyltransferase, and tubulin. For the temperature block reversal, and 
for all other time course experiments, immunofiuorescence and immuno- 
electron micrographs of cells at selected time points are shown in the fig- 
ures, 
Biochemical  Characterization of Caveolin in Isolated 
Subcellular Fractions 
The relative levels of caveolin in cytosol, plasma membrane, and intracel- 
lular membranes were  determined by immunoblotting of fractions iso- 
lated from cells cultured in 10 x  100-mm dishes in medium containing or 
lacking nocodazole. The procedure is based on an earlier study in which 
caveolin distributions were analyzed in cells that had been cultured in me- 
dium containing or lacking CO (27). In the present case, cells were treated 
with 50 ixg/ml cycloheximide for 2 h, during the last hour of which 40 IxM 
nocodazole or an equivalent volume of DMSO was also present. Next, 
each set of cells was collected by scraping, and was homogenized in 1 ml 
buffer A  (0.25 M sucrose, 1 mM EDTA, 20 mM tricine at pH 7.8) using a 
2-ml Wheaton tissue grinder (catalogue number 084146A). Each homoge- 
nate was then centrifuged for 10 rain at 1,000 g in an Eppendorf microcen- 
trifuge. The resulting postnuclear supernatant was stored on ice, and the 
pellet was homogenized and centrifuged exactly as was done earlier for 
the cells. The original and new postnuclear supernatants were combined, 
layered on top of 23 ml of 30%  Percoll in buffer A, and centrifuged at 
29,000 rpm (84,679 gmax)  for 30 min at 4  ° in a 60 Ti rotor (Beckman Instrs., 
Fullerton, CA). This centrifugation step yielded a layer of cytosol on top 
of the Percoll gradient, and two membrane fractions within the gradient. 
The  low  density fraction contained  highly purified  plasma membrane, 
while Golgi, ER, lysosomal, endosomal, and mitochondrial membranes 
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plasma membrane and intracellular membranes were collected from the 
Percoll gradient, and analyzed by SDS-PAGE (9) using 12.5% polyacryl- 
amide gels, and by immunoblotting (27, 32) with anti-caveolin. Each gel 
lane contained 50 p.g of protein, the secondary antibody was HRP-conju- 
gated  goat  anti-mouse IgG,  and  Pierce  SuperSignal  chemiluminescent 
substrate was used to detect immunoreactive caveolin. 
To analyze the accessibility of caveolin to trypsin in subcellular frac- 
tions obtained from control and nocodazole-treated cells, postnuclear su- 
pernatants were prepared exactly as described in the prior paragraph, ex- 
cept  that  lx  100-mm  culture  dish  was  used  per  experiment.  Each 
postnuclear supernatant was centrifuged at 43,000 rpm (100,000 gmax) for 
1 h  at 4  ° in a Beckman 100.3  rotor, yielding a  1-ml supernatant (soluble 
fraction) and a pellet (particulate fraction), which was resuspended in I ml 
buffer A. Each fraction was then incubated for 30 min on ice in the pres- 
ence or absence of 300 ixg/ml trypsin, after which soybean trypsin inhibi- 
tor was added to 300 ixg/ml.  Finally, each sample was precipitated with 
TCA (~7%  final concentration), resuspended in 25 p,1 sample buffer for 
SDS-PAGE,  and analyzed by SDS-PAGE  and Western blotting as de- 
scribed in the previous paragraph. 
Results 
Throughout this  study it was necessary to stain  cells for 
double immunofluorescence using a monoclonal IgG anti- 
body to caveolin and appropriate polyclonal antibodies in 
order to identify membrane compartments with which ca- 
veolin was associated.  The polyclonal antibody that was 
most extensively used was specific for the coatomer pro- 
tein,  [3-COP  (6, 25).  Anti-[3-COP stained both the Golgi 
and punctate membranes scattered  throughout the  cyto- 
plasm of normal human fibroblasts cultured in control me- 
dium (see Figs. 2 B and 4 B). The punctate structures were 
also labeled in control cells by a monoclonal antibody to 
ERGIC-53 (data not shown), an integral membrane pro- 
tein of the ER/Golgi intermediate  compartment, or ER- 
GIC (23). Partial colocalization of [3-COP with an ERGIC 
marker protein is consistent with prior reports that [3-COP 
is found on a membrane compartment through which the 
transmembrane glycoprotein of vesicular stomatitis  virus 
passes after leaving the ER and before entering the Golgi 
(6, 10). By definition, this compartment is the ERGIC (24). 
In cells that were treated for I h with 40 txM nocodazole, 
I3-COP, and ERGIC-53 remained partly colocalized. Anti- 
bodies to both proteins stained  the  ERGIC, while  anti- 
[3-COP  also labeled  Golgi fragments  that  resulted  from 
MT  disassembly  (Fig.  1, A  and  B).  After incubation  of 
cells at 15  ° for 2 h, which reportedly causes partial redistri- 
bution of ERGIC-53 to the Golgi (24), antibodies to either 
I3-COP or ERGIC-53 stained both the perinuclear Golgi 
and  the  widely scattered  ERGIC membranes  (Fig.  1,  C 
and D). Double labeling of cells with antibodies to [3-COP 
and the integral membrane Golgi marker, galactosyltrans- 
ferase, or with ERGIC-53 and galactosyltransferase, dem- 
onstrated unambiguous distinctions between the distribu- 
tions of Golgi and ERGIC membranes under all culture 
conditions used in this study (not shown). We concluded, 
therefore, that anti-[3-COP could be used to visualize the 
Golgi and  the  ERGIC in normal human fibroblasts cul- 
tured under a variety of conditions. 
Figure 1. 13-COP  is a marker for the Golgi and the ERGIC. Normal human fibroblasts were grown for i h in the presence of 40 IxM no- 
codazole (A and B) or for 2 h at 15  ° before being fixed and stained for double immunofluorescence using antibodies to [3-COP (A and 
C) and ERGIC-53 (B and D). Note the extensive colocalization of ~-COP and ERGIC-53 on punctate ERGIC membranes scattered 
throughout the cytoplasm in both sets of micrographs. In the nocodazole-treated cell, t3-COP (A), but not ERGIC-53 (B) can be seen on 
Golgi fragments located predominantly to the right of the nucleus. In the cell incubated at 15  °, both [3-COP  (C) and ERGIC-53 (D) can 
be seen at the Golgi apparatus, which is adjacent to the lower left edge of the nucleus. The bar in panel D equals 10 Ixm. 
Conrad et al. Microtubule-dependent Cycling of Caveolin  1423 Figure 2. CO-induced movement of caveolin to the Golgi requires MTs. The distributions of caveolin and 13-COP are shown by double 
immunofluorescence in normal human fibroblasts grown in control medium (A and B), in the presence of CO for 30 min (C and D), and 
in the presence of 40 ~M nocodazole for 30 min followed by a mixture of 40 ~M nocodazole plus CO (E and F). Note that caveolin was 
able to reach the Golgi in the cell treated with CO alone (compare C and D). When cells were pretreated with nocodazole to depoly- 
merize MTs, however, caveolin accumulated at 13-COP-positive  ERGIC membranes (arrows), but not at the [3-COP-positive Golgi. 
The bar in panel F equals 10 ~m. 
MTs Are Required for CO-induced  Transport of 
Caveolin to the Golgi 
To determine whether MTs are required for movement of 
caveolin  to  the  Golgi  in  CO-treated  human  fibroblasts, 
cells were cultured in the presence or absence of nocoda- 
zole  before  being  exposed  to  CO.  The  cells  were  then 
stained  for double immunofluorescence with  monoclonal 
anti-caveolin and polyclonal anti-[3-COP. In control cells, 
the  distributions  of caveolin  and  [3-COP did not overlap 
(Fig. 2, A  and B). Caveolin was most concentrated in dis- 
crete patches at the plasma membrane, while  I3-COP was 
found  on  the  Golgi  and  on  widely distributed,  punctate 
membranes of the ERGIC. Despite their distinct distribu- 
tions in control cells, caveolin and 13-COP were extensively 
colocalized in cells  treated  with 0.5  U/ml CO for 30 min 
(Fig.  2, C  and D).  In such cells,  both proteins were most 
abundant  at the Golgi, which had become somewhat dis- 
tended  as  a  result  of exposure  to  CO  (28).  In  addition, 
13-COP, but not caveolin, was detected  on ERGIC mem- 
branes in CO-treated cells. 
Although CO consistently induced movement of caveo- 
lin to the Golgi in cells that were not exposed to other per- 
turbants,  pretreatment  of cells  with  nocodazole  blocked 
this movement (Fig. 2, E  and F). After a 30-min incubation 
in  40  p~M  nocodazole,  which  completely  depolymerized 
MTs (data not shown), CO was added to the nocodazole- 
The Journal of Cell Biology, Volume 131,  1995  1424 Figure 3. MTs are not required for movement of caveolin from the Golgi to the plasma membrane after removal of CO. Normal human 
fibroblasts were exposed to CO for 30 min to redistribute caveolin to the Golgi, and then were cultured for an additional 20 min with 
CO in the presence of 40 p.M nocodazole, and finally were placed in CO-free medium containing  40 ~M nocodazole. After further incu- 
bations of 5, 15, and 60 min, ceils were fixed  and stained for double immunofluorescence using antibodies to caveolin and [3-COP 
(-MTs). For comparison, another set of cells was never exposed to nocodazole, but otherwise was treated identically (+ MTs). In either 
the presence or absence of MTs, most of the caveolin had exited the Golgi within 5 min of CO reversal (A-D). The caveolin at this time 
point was predominantly  in vesicle-like structures that did not colocalize with 13-COP, and therefore were not part of the ERGIC. Some 
caveolin was also present at the plasma membrane 5 min after CO was removed (A and C). By 15 min of CO reversal, the majority of 
the caveolin in cells containing or lacking MTs appeared to be at the plasma membrane, although some caveolin was still present on 
[3-COP-negative vesicles (E-H). After 60 min in CO-free medium, nearly all of the caveolin was at the plasma membrane in cells that 
contained MTs (/), but in cells that lacked MTs, caveolin was most concentrated in 13-COP-positive ERGIC membranes (K and L; see 
arrows). The bar in panel L equals 10 p.m. 
containing  medium to a final concentration of 0.5 U/ml. In 
cells that were fixed 30 min later, the Golgi remained par- 
tially intact near the cell center, as evidenced by staining 
with  anti-13-COP,  which  also  labeled  widely  scattered 
punctate membranes of the ERGIC. The caveolin in such 
cells was not localized at the Golgi, but instead was restricted 
to the ERGIC. Thus, in cells that lacked MTs, caveolin ac- 
cumulated in the ERGIC and was unable to move to the 
Golgi in response to CO. 
MTs Are Not Required for Movement of Caveolin from 
the Golgi to the Plasma Membrane after Removal of CO 
To determine whether MTs are involved in moving caveo- 
lin to the cell surface following CO removal, it was neces- 
sary first to accumulate caveolin at the  Golgi using CO, 
then to disassemble MTs, and finally to remove the CO. This 
was accomplished by treating cells with 0.5 U/ml CO for 30 
min, then with 0.5 U/ml CO plus 40 IxM nocodazole for 20 
min, and finally with CO-free medium containing or lack- 
Conrad et al. Microtubule-dependent Cycling of Caveolin  1425 ing 40 txM nocodazole. At various times thereafter, cells 
were  fixed  and  stained  for  double  immunofluorescence 
with antibodies to caveolin and 13-COP. MTs were not ob- 
served in cells  that were maintained in nocodazole after 
CO  reversal,  but  extensive  MT networks were  found in 
cells within 10 min after removal of both nocodazole and 
CO (data not shown). 
Within 5 min after CO was removed from cells contain- 
ing or lacking MTs, caveolin had exited the Golgi and was 
present primarily in punctate structures that did not colo- 
calize  with  ERGIC/Golgi  membranes  stained  by  anti- 
13-COP. Some staining of the plasma membrane by anti- 
caveolin was also seen after 5 min of CO reversal, whether 
or not MTs were present (Fig. 3, A-D). In both MT-con- 
taining and MT-depleted cells, the majority of the caveolin 
appeared to be at the plasma membrane 15 min after re- 
moval  of  CO,  with  the  remainder  being  present  on 
13-COP-negative vesicles (Fig.  3, E-H).  After 60 min of 
CO reversal, nearly all caveolin in MT-containing cells was 
at the cell surface (Fig. 3/). In contrast, 60 min after CO 
was removed from cells lacking MTs, caveolin was found 
predominantly  in  the  cytoplasm  on  punctate  structures 
that colocalized with ~-COP, and to a lesser extent at the 
plasma membrane (Fig.  3, K  and L). These results  indi- 
cated that after CO removal, MTs are not necessary for 
caveolin to move from the Golgi to the plasma membrane, 
but are required for caveolin to accumulate there prefer- 
entially. In the absence of MTs, far more caveolin accumu- 
lated in the ERGIC/Golgi than at the plasma membrane. 
Caveolin Redistributes to the ERGIC after Treatment 
of Cells with Nocodazole Alone 
The  observed  accumulation  of caveolin  in  the  ERGIC/ 
Golgi after removal of CO from nocodazole-treated cells 
(see Fig. 3) suggested that the normal steady-state enrich- 
ment of caveolin in caveolae is sensitive not only to choles- 
terol oxidation by CO, but to disassembly of MTs as well. 
To test this idea, the distributions of caveolin and [3-COP 
were  examined  by  double  immunofluorescence  in  cells 
that had been treated with nocodazole alone. 
Before nocodazole addition,  caveolin was  located  pri- 
marily at the cell surface, while I3-COP was most promi- 
nent at the Golgi, but was also evident on widely dispersed 
ERGIC membranes (Fig. 4, A and B; also see Fig. 2, A and 
B). Within 30 min of exposure to 40 IxM nocodazole, caveo- 
lin colocalized with 13-COP at peripherally distributed mem- 
branes of the ERGIC, and was also detectable at the plasma 
membrane. The Golgi complex remained partially intact 
near the cell center under these conditions, as indicated by 
the antibody to 13-COP, but caveolin was not detectable at 
the Golgi (Fig. 4, C and D). Caveolin and [3-COP remained 
extensively colocalized after 90 min of nocodazole treat- 
ment,  at which point caveolin was nearly gone from the 
Figure 4. Nocodazole induces 
caveolin to redistribute from 
the plasma membrane to the 
ERGIC. The distributions of 
caveolin  and  13-COP  are 
shown by double immunoflu- 
orescence  in  normal  human 
fibroblasts  grown in  control 
medium  (A  and  B),  and  in 
the  presence  of 40  txM  no- 
codazole for 30 (C and D), or 
90 (E and F) min. Note that 
caveolin  redistributed  from 
its  control  location  at  the 
plasma  membrane  (A  and 
B)  to  [3-COP-positive ER- 
GIC membranes  in nocoda- 
zole-treated  cells (C-F).  Re- 
sidual  Golgi  membranes 
located near the nuclei of the 
nocodazole-treated cells were 
stained  by anti-13-COP, but 
not by anti-caveolin. The bar 
in panel F equals 10 ~m. 
The Journal of Cell Biology,  Volume 131, 1995  1426 Figure 5. Removal of nocodazole induces caveolin to redistribute from the ERGIC to the plasma membrane after passing through the 
Golgi. The distributions of caveolin, 13-COP and tubulin (MT) are shown by triple immunofluorescence in normal human fibroblasts cul- 
tured in the presence of 40 ~M nocodazole for 1 h before transfer to nocodazole-free medium. Within 30 min of nocodazole reversal, by 
which time MTs were abundant (C), caveolin migrated from the ERGIC (see Fig. 4) to the 13-COP-positive Golgi (A and B). After 60 
min in the absence of nocodazole, caveolin returned  to its normal steady-state location predominantly  at the plasma membrane  (D). 
The bar in panel F equals 10 Ixm. 
plasma membrane and only small,  [3-COP-:positive rem- 
nants of the Golgi remained near the nucleus. Anti-caveo- 
lin did not stain the residual Golgi membranes (Fig.  4, E 
and F). These observations demonstrate that caveolin re- 
distributes from the plasma membrane to the ERGIC af- 
ter disassembly of MTs. Moreover, they imply that after 
removal  of  CO  from  nocodazole-treated cells,  caveolin 
moved from the Golgi to the plasma membrane, and then 
to the ERGIC (see Fig. 3). 
Nocodazole Reversal Causes Caveolin to Move 
Synchronously from the ERGIC to the Golgi, and then 
to the Plasma Membrane 
To determine whether the effects of MT disassembly on 
caveolin were  reversible,  cells  were  treated  with 40 p.M 
nocodazole for 1 h,  after which they were transferred to 
nocodazole-free medium. At 10-min time intervals there- 
after, cells were fixed and stained for triple immunofluo- 
rescence using antibodies to caveolin, [3-COP, and tubulin. 
Fig. 5 illustrates  the results  of a  typical experiment 30 
and 60 min  after removal of nocodazole. At the  30-min 
time point, when the MT network had fully reformed, cav- 
eolin was most concentrated near the cell center, where it 
was extensively colocalized with [3-COP at the Golgi (Fig. 
5, A-C). In contrast, caveolin and [3-COP were not colo- 
calized at 60 min of nocodazole reversal. Whereas caveolin 
had  returned  to the  plasma  membrane,  [3-COP  was still 
most abundant at the Golgi (Fig. 5, D-F). Taken together, 
these results demonstrate that the effects of nocodazole on 
the distribution of caveolin are fully reversible, but that cav- 
eolin  does  not  return  directly to  the  plasma  membrane 
from the ERGIC after removal of nocodazole. Instead, cav- 
eolin travels from the ERGIC to the Golgi, before com- 
pleting its journey back to plasma membrane caveolae. 
Caveolin Moves Reversibly from the 
Plasma Membrane to the Golgi after Release of Cells 
from a 15°Temperature Block 
To test the possibility that CO and nocodazole act by im- 
posing reversible roadblocks along a pathway that is nor- 
mally followed by caveolin in  unperturbed  cells,  a  third 
potential perturbant of caveolin, incubation of cells at 15  °, 
was investigated. It is well established that materials which 
normally move to the Golgi are effectively blocked at pre- 
Golgi sites when cells  are held at 15  °, and move en masse 
to the Golgi and beyond after the cells are returned to 37  ° 
(10, 20, 24). 
Shown in Fig. 6 are the results of a  temperature block 
experiment, in which cells were double labeled with anti- 
bodies to caveolin and [3-COP. After cells were incubated 
at 15  ° for 2 h, caveolin was still  localized primarily at the 
plasma membrane, and [3-COP was found both on the cen- 
trally located Golgi and throughout the ERGIC (Fig. 6, A 
and B). Compared to unperturbed cells (see Figs. 2 B and 
4  B),  these  temperature  blocked  cells  contained  Golgi 
complexes that  were  diminished  in  size,  and  staining  of 
ERGIC membranes by anti-13-COP was enhanced. When 
the cells were transferred to 37  °, most of the detectable cav- 
eolin moved to the ERGIC within 10 min, at which point 
the distribution of ~-COP had not yet changed apprecia- 
bly (Fig. 6, C and D). After 30 min at 37  °, however, both 
caveolin and  13-COP had  moved to  the  Golgi, the  mor- 
phology of which appeared to have fully recovered from 
the temperature block (Fig. 6, E and F). Within an hour of 
Conrad et al. Microtubule-dependent Cycling of Caveolin  1427 Figure 6. Release of cells from a cold block at 15  ° induces caveolin to move from the plasma membrane to the ERGIC, and then to the 
Golgi. The distributions of caveolin and B-COP are shown by double immunofluorescence  in normal human fibroblasts that were incu- 
bated for 2 h at 15  ° before transfer to 37  °. Immediately after the cold block, most of the caveolin was located at the plasma membrane 
(A), and the B-COP-positive Golgi was somewhat fragmented (B). After 10 min at 37  °, caveolin was virtually absent from the plasma 
membrane, and colocalized  with B-COP at ERGIC membranes (C and D; see arrows),  but not at the Golgi, which remained frag- 
mented. After a 30-min incubation at 37  °, most of the caveolin moved to the B-COP-positive Golgi, which now appeared relatively in- 
tact (E and F). The bar in panel F equals 10 Ixm. 
recovery  at  37  °,  caveolin returned  to  the  plasma  mem- 
brane. 
When cells were held at 15  ° for 2 h, and were then incu- 
bated at 37  ° sufficiently long to permit synchronous trans- 
port of caveolin to the Golgi, subsequent addition of no- 
codazole did not block movement of caveolin back to the 
plasma  membrane.  In  contrast,  when  nocodazole  was 
added  at  the  same  time as  the  shift to  37  °,  caveolin re- 
mained in the ERGIC and did not reach the Golgi (data 
not shown). Based on these collective results, we conclude 
that temporary incubation of cells at 15  °  , like transient ex- 
posure of cells to CO or nocodazole, reveals a cyclic traf- 
ficking pathway for caveolin that leads from the plasma 
membrane to the Golgi via the ER and ERGIC, and then 
from the Golgi back to plasma membrane. Moreover, as 
was found for.addition and removal of CO (see Figs. 2 and 
3),  MTs are  required for transport of caveolin from the 
ERGIC to  the  Golgi, but not for the  return of caveolin 
from Golgi to the plasma membrane after release of cells 
from a 15 ° temperature block. 
Characterization  of the Caveolin Trafficking 
Cycle by Immuno-EM 
The caveolin internalization cycle was  confirmed by im- 
munogold EM, as shown in Fig. 7. Nearly all of the caveo- 
lin in control cells grown at 37  ° was in caveolae. Only a few 
gold particles were seen scattered in the lumen of the rough 
ER, in tubulovesicular organelles, or in the Golgi (Fig. 7 
A). Caveolin was still primarily in caveolae after 2 h at 15  °, 
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the  caveolin  trafficking  cycle 
by  immunogold  EM.  Normal 
human  fibroblasts  were  cul- 
tured  in control medium  (A), 
for 2 h at 15  ° before transfer to 
37  ° for 0 (B), 20 (C), or 40 (D) 
min, or for 1 h  in 40 p,M no- 
codazole  (E).  In control cells 
(A) and cells  incubated at 15  ° 
for 2 h (B), most gold particles 
were  found  at  plasma  mem- 
brane  caveolae (---)), although 
partial redistribution of caveo- 
lin to the lumen of the ER (~) 
was seen in cold-blocked cells. 
Within 20 min after cells were 
returned  to  37°(C),  caveo- 
lin  was evident in the lumens 
of  tubulovesicular  structures 
(~),  which presumably corre- 
sponded to the ERGIC. By 40 
min at 37  ° (D), gold particles 
(=) were abundant within the 
lumens  of  swollen  Golgi 
stacks.  In  nocodazole-treated 
cells  (E),  caveolae  were 
readily  visible  (--~), but  were 
nearly devoid of immunogold 
particles.  Instead,  most  gold 
particles  (~)  were  located 
within  vesicle-like  structures 
that  presumably  represented 
the ERGIC. The bar in panel 
A equals 0.5 ixm. 
although  labeling  of  ER  and  tubulovesicular  structures 
was more noticeable than in controls (Fig. 7 B). Soon after 
cells that had been incubated for 2 h at 15  ° were shifted to 
37  °, the distribution of caveolin changed dramatically. Af- 
ter 20 min at 37  °, caveolin was no longer found in caveo- 
lae, but instead was located in the lumen of tubulovesicu- 
lar structures (Fig. 7 C). The appearance of these structures 
was consistent  with  their  identification  as  ERGIC  mem- 
branes, particularly in light of the immunofluorescence ev- 
idence establishing that caveolin accumulates in the ERGIC 
shortly after  release  of cells  from 15  ° (see Fig.  6).  By 40 
min  at  37  °,  caveolin  had  moved to  the  lumens  of Golgi 
stacks, which still appeared swollen as a result of the prior 
cold block (Fig. 7 D). Within 60 min of returning the cells 
to 37  °, most of the caveolin had reached plasma membrane 
caveolae (data not shown). Finally, in cells incubated for 1 h 
at 37  ° in the presence  of 40  p~M nocodazole the caveolin 
was in the lumen of vesicles that presumably were part of 
the  ERGIC, and was  also  associated  with  caveolae.  The 
caveolae  in  these  nocodazole-treated  cells  had  a  normal 
morphology and were slightly less abundant  than in con- 
trol cells (Fig. 7 E). 
The Half-Life of Caveolin 
Taken together, the data described so far suggest the exist- 
ence  of a  constitutive  transport  cycle in  which  caveolin 
moves reversibly between plasma membrane caveolae and 
the Golgi in normal, unperturbed cells (see Fig. 10 and the 
Discussion  section).  This  interpretation  might be  fawed, 
however, if the half-life of caveolin were short relative to 
the  time  periods  for which cells were exposed  to pertur- 
bants such as CO, nocodazole or 15  °.  If its  half-life were 
short, the caveolin that was observed to move through the 
ER,  ERGIC,  and  Golgi  might  simply  have  been  newly 
synthesized protein traveling through successive compart- 
ments  of the  secretory pathway,  rather  than  pre-existing 
caveolin undergoing a normal transport cycle. 
To resolve this  ambiguity, the half-life  of caveolin was 
determined by immunoprecipitation from cells pulsed with 
[35S]methionine  and  chased  with  unlabeled  methionine. 
Radiolabeled  caveolin was detectable  by immunoprecipi- 
tation until 20 h of chase. The half-life of caveolin is there- 
fore ~10 h, or about 5 times longer than the longest exper- 
iment shown in Figs.  2-7. We also repeated  many of the 
immunofluorescence  time  course  experiments  using cells 
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ning 1 h before exposure to CO, nocodazole, or 15  °. Cyclo- 
heximide did not detectably alter any of the immunofluo- 
rescence results. Evidently, therefore, the collective results 
shown in Figs. 2-7 indicate the behavior of pre-existing cav- 
eolin,  and  their  interpretation  should  not be  clouded  by 
any newly synthesized caveolin that may have been present 
in the cells. 
Biochemical Characterization of the Caveolin 
Transport Cycle 
The  immunofluorescence  and  immunoelectron  micro- 
scopic data  documented  in Figs.  2-7 imply that  caveolin 
travels through the cytoplasm in association with intracel- 
lular membranes, and is intraluminal when localized at the 
ERGIC and Golgi. To investigate caveolin transport by a 
different  approach, the distribution  of caveolin was stud- 
ied in two sets of experiments  by biochemical analysis of 
isolated  subcellular  fractions.  In  both  cases,  cells  were 
treated for I  h with 50 Ixg/ml of cycloheximide, after which 
they were cultured for an additional hour with or without 
40 I~M nocodazole in the continued presence of cyclohex- 
imide. The cells were then homogenized, and postnuclear 
supernatants were prepared. 
The aim of the first group of experiments was to docu- 
ment the movement of caveolin from plasma membrane to 
internal  cellular  membranes.  Each  postnuclear  superna- 
tant was fractionated on a Percoll gradient, yielding three 
distinct  fractions  (27):  cytosol,  highly  purified  plasma 
membrane, and intracellular membranes (Golgi, ER, lyso- 
somes, endosomes, mitochondria, etc). An aliquot of each 
fraction containing 50 ~g of protein was then analyzed by 
immunoblotting with anti-caveolin. As illustrated in Fig. 8 
A, all of the detectable  caveolin was in the plasma mem- 
brane  fraction  isolated  from control cells.  In the  case  of 
nocodazole-treated cells,  however, caveolin was detected 
solely in the  intracellular  membrane  fraction.  These  bio- 
chemical results  confirm that  caveolin redistributes  from 
the plasma membrane to intracellular  membranes follow- 
ing treatment of cells with nocodazole. 
The next set of experiments was designed to determine 
whether the redistributed  caveolin was located within the 
lumen  of intracellular  membranes.  First,  the  postnuclear 
supernatants  were  centrifuged  at  100,000 gmax for 1  h  to 
yield soluble and particulate fractions. Next, each fraction 
was incubated for 30 min on ice in the presence or absence 
of trypsin.  Finally,  all  of the  fractions  were  analyzed  by 
anti-caveolin immunoblotting.  Fig. 8 B  demonstrates  that 
caveolin quantitatively cofractionated with particulate mem- 
branes in both control and nocodazole-treated cells,  con- 
sistent with the results shown in Fig. 8 A. In addition, Fig. 
8 B  shows that trypsin could fully degrade caveolin when 
caveolin  was  associated  with  the  plasma  membrane,  but 
not  when  it  was  associated  with  internal  cellular  mem- 
branes  unless  they  first  had  been  solubilized  with  SDS. 
These  results  are  consistent  with  immuno-EM  evidence 
that caveolin is exposed to the cytoplasm when associated 
with plasma membrane caveolae, but is located within the 
lumens of intracellular membrane-bounded compartments 
of nocodazole-treated cells (see Fig. 7). 
Caveolin Is Not Associated with Endosomes 
or Lysosomes 
Even though immunofluorescence data indicated an accu- 
mulation of caveolin in the ERGIC of nocodazole-treated 
cells (Figs. 2, 4, and 7), the results of the protease protec- 
tion experiments  (Fig. 8) raised the alternative  possibility 
that  nocodazole induces  caveolin  to be  internalized  into 
endosomes.  To  investigate  that  possibility,  cells  were 
treated with 40 txM nocodazole for 1.5 h, after which they 
were  fixed  and  stained  for  double  immunofluorescence 
Figure 8. Biochemical characterization of the caveolin trafficking 
cycle.  Cells  were treated  for 1 h  with cycloheximide to inhibit 
protein  synthesis,  after which  they were  cultured  for an  addi- 
tional hour with or without 40 txM nocodazole in the continued 
presence  of cycloheximide. The  cells  were  then  homogenized, 
and postnuclear supernatants were prepared. (A) Postnuclear su- 
pernatants were fractionated on Percoll gradient, yielding three 
distinct  fractions (27): cytosol, highly purified plasma membrane, 
and intracellular membranes (Golgi, ER, lysosomes, endosomes, 
mitochondria, etc).  An aliquot of each fraction containing 50 ~g 
of protein was then analyzed by immunoblotting with anti-caveo- 
lin.  As  shown  here,  all  of the  detectable  caveolin  was  in  the 
plasma membrane fraction isolated from control cells. In the case 
of cells treated with nocodazole (NOC), however, caveolin was 
detected solely in the intracellular membrane fraction. (B) Post- 
nuclear supernatants were centrifuged at 100,000 grnax  for 1 h to 
yield soluble and particulate fractions.  Each fraction was then in- 
cubated for 30 min on ice in the presence or absence of trypsin, 
and subsequently was analyzed by immunoblotting with anti-cav- 
eolin.  It is  evident  that  caveolin  quantitatively  cofractionated 
with  the  particulate  fraction  in  both  control  and  nocodazole- 
treated  cells.  In addition,  trypsin fully  degraded caveolin when 
caveolin was associated with the plasma membrane, but not when 
it  was associated with internal  cellular membranes  unless  they 
were solubilized  with SDS. 
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C) and an endosomal marker, the LDL receptor (B), or a lysosomal marker, cathepsin D (D), are shown by double immunofluorescence 
in normal human fibroblasts cultured in the presence of 40 txM nocodazole for 1.5 h. Note that the distributions of caveolin and the LDL 
receptor or cathepsin D overlap only marginally. The bar in panel D equals 10 ixm. 
with monoclonal anti-caveolin and a polyclonal antibody 
to either the LDL receptor or cathepsin D, which served 
as markers for endosomes and lysosomes, respectively. As 
shown in Fig. 9, the distributions of caveolin and the LDL 
receptor or cathepsin D overlapped only marginally in no- 
codazole-treated cells.  These results rule out the possibil- 
ity that exposure of cells to nocodazole induces caveolin to 
accumulate preferentially in endosomes or lysosomes. Fur- 
thermore, the results are fully consistent with the evidence 
shown in Figs. 2, 4, and 7 that caveolin is localized in the 
ERGIC of nocodazole-treated cells. 
Discussion 
Many structurally and functionally distinct compartments 
within  the  secretory and  receptor-mediated  endocytotic 
pathways have been found to be dynamic structures whose 
maintenance depends upon a balance between the influx 
and efflux of proteins and lipids that are exchanged with 
adjacent compartments of the pathways. The vehicles for 
transport between compartments are often tubulovesicu- 
lar structures  that move along MTs.  For example,  tubu- 
lovesicular membranes of the ERGIC are responsible for 
bidirectional, MT-based transport of material between the 
ER and the Golgi (10, 11). 
The study described here was based on the hypothesis 
that caveolae, like the ER, the Golgi, and other classes of 
quasi-stable membrane compartments, are dynamic struc- 
tures that depend upon MT-based transport to exchange 
materials with other compartments. Based on the recent 
finding  that  CO  reversibly  causes  the  resident  caveolar 
protein, caveolin, to relocate from the plasma membrane 
to the Golgi (28), we decided to explore the possibility that 
CO had revealed a normal cyclic transport pathway for cav- 
eolin. 
We found that a cyclic pathway for the trafficking of cav- 
eolin through multiple membrane compartments could be 
detected in cells that were transiently exposed not only to 
CO, but  also to nocodazole or 15  °.  Regardless  of which 
single  perturbant  or  combination  of  perturbants  were 
used, a unique overall pathway comprising a unique set of 
consecutive steps was consistently observed. Dissection of 
the pathway into distinct, individual steps was possible be- 
cause each perturbant that was analyzed, CO, nocodazole 
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within  the  pathway.  Because  the  same  pathway  was  re- 
vealed by three different perturbants  whose modes of ac- 
tion are mutually distinct, we strongly favor the hypothesis 
that a specific cyclic pathway, which is summarized in Fig. 
10, is normally followed by caveolin in unperturbed cells. 
The  initial  inward  step  of the  pathway  leads  caveolin 
from plasma membrane caveolae to the ER. Incubation of 
cells at 15  ° for 2 h  apparently blocks this step specifically, 
because within minutes after cells are returned to 37  °, cav- 
eolin  exits  the  plasma  membrane  synchronously and  en 
masse (see Fig. 6). Evidently, this block is effective, but in- 
complete,  because  more  caveolin  was  detected  by  im- 
muno-EM in the ER of cold-blocked cells than of control 
cells  (see Fig. 7).  After reaching the ER, caveolin moves 
next to the ERGIC and then to the Golgi. Passage of cav- 
eolin  through  the  two  latter  compartments  was  docu- 
mented throughout the present study by colocalization of 
caveolin with  [3-COP, a  marker for both the ERGIC and 
the Golgi. By comparison, caveolin did not colocalize with 
markers  for  endosomes  or  lysosomes  after  exiting  the 
plasma membrane and ER (see Fig. 9). Because caveolin 
was able to reach the ERGIC, but not the Golgi, in CO- 
treated  cells  that  were  also  exposed  to  nocodazole  (see 
Fig. 2), or in cells treated with nocodazole alone (see Fig. 
4), movement from the ERGIC to the Golgi evidently re- 
quires  MTs.  In contrast,  the  return  of caveolin from the 
Golgi  to  the  plasma  membrane  apparently  does  not  re- 
quire MTs, because nocodazole did not block this step of 
the cycle in cells that were released  from either  CO  (see 
Fig. 3) or a  15  ° temperature  block (data not shown). It is 
also  noteworthy  that  the  Golgi-to-cell  surface  step  does 
not appear to occur via the ERGIC, because caveolin did 
not colocalize with  13-COP during  this  stage  of the  cycle 
(see Fig. 3). 
In light of the fact that ~90% of the caveolin recognized 
by  the  monoclonal  anti-caveolin  used  throughout  this 
study  is  localized  in  caveolae  at  steady  state  in  unper- 
turbed cells (7, 19), we propose that the rate-limiting step 
in the normal cycle is movement of caveolin from caveolae 
to the ER.  In CO-treated  cells  (see Fig. 2), however, the 
rate-limiting  step  appears to be transport  from the Golgi 
back to the plasma membrane, because caveolin accumu- 
lates in the Golgi or post-Golgi vesicles after exposure of 
cells to CO (28). While this could be due to CO blocking 
transport at the Golgi-to-plasma membrane step, it might 
alternatively reflect, as we suspect, a  CO-mediated accel- 
eration  of  caveolin  movement  off  of the  plasma  mem- 
brane.  Perhaps  oxidized  caveolar  cholesterol,  which  in- 
creases  dramatically after cells are treated  with  CO (28), 
stimulates  movement of caveolin from caveolae into  the 
ER.  The  entire  cycle has  been  observed  in  cells  treated 
with  cycloheximide  (see Fig.  8, and  [28]),  indicating  that 
whatever  contributions  newly  synthesized  caveolin  may 
have made to the data documented in Figs. 2-7, the issue 
of caveolin synthesis is irrelevant to the model depicted in 
Fig. 10. Finally, it must be emphasized that the existence of 
transport  steps  not specified  in the model,  such as direct 
movement of caveolin from the ER to the plasma mem- 
brane,  cannot be ruled out by the data that are currently 
available. 
The  pathway  summarized  in Fig.  10 is  consistent  with 
the existing data for only one component of caveolae, the 
coat-associated  protein,  caveolin.  There  is  a  very recent 
report  that  apparently  intact  caveolae can be  induced to 
move from the plasma membrane  to the cell center by a 
MT-dependent process after exposure of cells to the pro- 
tein phosphatase inhibitor, okadaic acid, in the presence of 
hypertonic medium  (16).  Our evidence implies  that  bulk 
transport  of caveolae  between  the  cell  surface  and  the 
Golgi does not normally occur, but does not rule out the 
possibility  that  multiple  components  of caveolae  follow 
the same bidirectional pathway traveled by caveolin. 
What functions could be served by the cyclic transport 
of caveolin?  One  possibility  worthy of serious  consider- 
ation  is  that  caveolin  carries  exogenous fatty acids  from 
their  sites of uptake at the plasma membrane to the ER, 
where they are converted to membrane lipids. Underscor- 
ing this possibility is the recent finding that caveolin binds 
a long chain fatty acid with high affinity (Anderson, R. G. W., 
unpublished observations). In light of this discovery, it will 
be worthwhile to examine whether fatty acids and the lip- 
Figure 10.  A  model for the constitutive trafficking of caveolin. 
The collective data presented in this report suggest that caveolin 
normally undergoes constitutive  cycling between  plasma mem- 
brane caveolae and the Golgi complex. The cycle evidently leads 
sequentially from caveolae to the ER, the ERGIC, the Golgi, and 
finally  back to the plasma membrane. Because most caveolin is 
localized in caveolae at  steady state  in  unperturbed  cells  (see 
Figs. 2 A and 4 A), it seems likely that the rate limiting step in the 
normal cycle is movement from caveolae to the ER. This step 
seems to be inhibited when cells are incubated at 15  °, because re- 
turn of cells to 37  ° leads to the rapid, synchronous movement of 
caveolin through the cycle (see Fig. 6). One step, from the ERGIC 
to the  Golgi, is blocked by nocodazole, and therefore requires 
MTs (see Figs. 2 and 4). Transport from the Golgi to the plasma 
membrane is MT independent, and occurs via apparent vesicular 
intermediates that do not colocalize with 13-COP, and therefore 
seem to be distinct  from the ERGIC (see Fig. 3). The buildup of 
caveolin in the Golgi of CO-treated cells implies  that the Golgi- 
to-plasma membrane step is rate limiting  in the presence of CO. 
This could be due to CO accelerating the caveolae-to-ER step or 
inhibiting  the  Golgi-to-plasma membrane step.  Presently avail- 
able data do not allow us to discriminate between these possibili- 
ties.  Finally,  while  the  model  shown  here  is  consistent  with 
present evidence, it does not exclude additional steps that theo- 
retically could occur, such as direct bidirectional  transport  be- 
tween the plasma membrane and the ER. 
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caveolin as it cycles between caveolae and the Golgi. Bidi- 
rectional  transport  of caveolin  could  also  serve  the  pur- 
pose  of returning  resident  Golgi  proteins  that  escape  to 
the plasma membrane because they are incorporated into 
secretory vesicles that are delivered to the cell surface. 
Regardless  of what functions  may be  served  by  cyclic 
transport between caveolae and the Golgi, the results pre- 
sented here emphasize a novel protein transport pathway 
that coincides, at least in part, with the route followed by 
nascent  secretory  proteins  and  lipids.  Not  only do  those 
newly synthesized products travel successively through the 
ER,  the  ERGIC  and  the  Golgi,  before  travelling  to  the 
plasma  membrane  in  Golgi-derived  vesicles,  but  so  too 
does at least one resident protein of cell surface caveolae. 
That protein, caveolin, appears to follow this route consti- 
tutively and, we presume, repetitively. The challenge now 
is to learn why this occurs, and to determine whether other 
caveolar  components  undergo  similar  cycling.  Several 
other important issues that are raised by the present study 
warrant  attention  in  the  near  future.  Foremost  among 
those issues are the identity of the MT motor responsible 
for  moving caveolin  from the  ERGIC  to  the  Golgi,  the 
MT-independent  mechanism  by  which  caveolin  moves 
from the Golgi to the plasma membrane, and the mecha- 
nism by which caveolin is converted between a cytoplasmi- 
cally oriented membrane protein at the cell surface and an 
intraluminal  protein  when  associated  with  intracellular 
membranes. 
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